Wang et al. used a genetic proxy of angiopoietin-like proteins 3 and 4 (ANGPTL3 and ANGPTL4) and lipoprotein lipase (LPL) to demonstrate an association with lipoprotein lipids and fatty acids, and employed drug-target MR to reveal that modulating coronary heart disease and type 2 diabetes risk at the ANGPTL4 and LPL loci was predicted to be clinically beneficial with concomitant predicted effects on WHR, whereas an ANGPTL3 variant showed a distinct effect on renal function.84 Here, LPL is linked to coronary artery disorder.